RTW Biotech Opportunities Ltd (LON:RTW), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, has noted the announcement by private portfolio company Windward Bio Group AG of the pricing of its initial public offering (IPO). Windward sold 10 million shares of common stock at $17 per share, for gross proceeds of approximately $175 million. Sanofi is concurrently investing $50 million in a private placement at the IPO price, bringing total gross proceeds to $225 million.
Windward is a clinical-stage biotech developing antibody medicines engineered to be long acting and offer a more convenient product presentation for patients with serious respiratory and dermatologic diseases. Its lead programme, WIN378, is being studied in asthma and chronic obstructive pulmonary disease and is currently in a Phase 2/3 trial for asthma and Phase 2 for COPD.
RTW Bio first invested $5.3 million in Windward’s Series A in January 2025 and a further $1.7 million in its $165 million Series B crossover, for a total investment of $7.0 million.
Windward began trading on the Nasdaq Global Select Market under the ticker “WWB” on 13 November 2026, where the shares traded up 68% to close at $28.50 on the day. Overall, this first day closing valuation represents a 180% step-up from RTW Bio’s prior holding value at 31 October 2026 and a 196% step-up from cost. Prior to the uplift in value, as at 31 October 2026, Windward represented 0.8% of RTW Bio’s NAV valued at $7.4 million.
Windward is RTW Bio’s tenth go-public event from its portfolio in 2026, following the IPOs of Aktis in January, Kailera in April, City Therapeutics in October and Lycia in October and five reverse or SPAC mergers announced or completed. The IPO window has reopened decisively in 2026 and public investors are placing a premium on late-stage assets with a clear durability or convenience advantage. Large-cap pharma, facing a cumulative patent cliff of approximately $170 billion by 2032, continues to look for differentiated assets. A crossover investment ahead of a listing positions RTW Bio to benefit from both dynamics.
Josh Kennedy-Smith, Partner and Head of Inflammation & Immunology at RTW Investments, LP, said, “Windward’s lead antibody targets a well-validated pathway in respiratory disease and may be dosed twice a year rather than monthly for most standard of care biologics prescribed today. This enhanced product profile compelled us to invest in the Series A, and the superb clinical execution by the team is why we added in the crossover round and at the IPO. We are excited to offer our continued support of Windward Bio as they bring their pipeline forward.






































